kinase

(redirected from Tyrosine kinase)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Tyrosine kinase: Tyrosine Kinase Receptor

kinase

[′kī‚nās]
(biochemistry)
Any enzyme that catalyzes phosphorylation reactions.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
This edition summarizes "Overview of Second-Generation Tyrosine Kinase Inhibitors for Patients With Imatinib-Resistant Chronic Myelogenous Leukemia" by Patricia Ault, RN, MS, ACCNP, NP-C, FNP-C, which was featured in the February 2007 issue of CJON.
That changed when other scientists showed that the drug imatinib mesylate, or Gleevec, can thwart chronic myelogenous leukemia in animals and people by inhibiting another mutant tyrosine kinase (SN: 12/11/99, p.
Several well-published clinical studies including AURA, AURA2, FLAURA, ENSURE, EURTAC and FASTACT2 have now demonstrated that the cobas EGFR Mutation Test v2 is a robust and reliable diagnostic test and is able to identify those patients to respond to EGFR tyrosine kinase inhibitor (TKI) therapies,said the company.
[USPRwire, Fri Aug 23 2019] This report on the tyrosine kinase inhibitors market analyzes the current and future scenario of the global market.
[ClickPress, Fri Aug 23 2019] This report on the tyrosine kinase inhibitors market analyzes the current and future scenario of the global market.
The patients must be previously treated with imatinib and one or two additional tyrosine kinase inhibitors.
has announced that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion.
N-terminal (JH 7) of Jak molecule has a receptor binding site while C-terminal (JH 1) is responsible for catalytic activity.1,3 These regions have four functional domains, which includes a FERM (band 4.1, ezrin, radixin, moesin), an SH2 (Src homology 2) like domain, a tyrosine kinase and kinase-like pseudokinase domain.4,6-8
Vitrakvi works for patients whose cancer tests positive for a type of mutation called a gene fusion in a gene called the neurotropic receptor tyrosine kinase, NTRK.
Patients who were in accelerated/blast phase, or already taking any Tyrosine Kinase Inhibitors or chemotherapy were excluded from the study.
Published online, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors" continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment.

Full browser ?